MYBL1 and central nervous system neoplasm: PDLGG, a new category in the WHO CNS tumors classification 2021, comprises four tumors showing MYB/MYBL1 fusion with a partner gene or MAPK pathway activating mutations involving primarily BRAF or FGFR1. However, this classification is still in its early stages and presents some confusion.